Literature DB >> 2470072

Disposition and tumor localization of mitomycin C-dextran conjugates in mice.

Y Takakura1, A Takagi, M Hashida, H Sezaki.   

Abstract

Mitomycin C-Dextran conjugates (MMC-D) were intravenously (iv) injected in mice bearing subcutaneous sarcoma 180. The tissue distribution was determined for three 14-C-labeled anionic conjugates (MMC-Dan) with molecular weights of 10, 70, and 500 kd and one cationic 70-kd 14C-conjugate (MMC-Dcat). The anionic conjugates were slowly cleared from the plasma, and their elimination rate decreased with increasing molecular weight. Radioactivity accumulated in liver, spleen, lymph nodes, and tumor but not in heart, lung, intestines, kidney, or muscle after iv injection of all types of 14C-MMC-Dan. In contrast, the cationic conjugate was rapidly cleared from the plasma and accumulated mostly in the liver and spleen, while tumor levels remained low. The antitumor effect of the 70-kd MMC-Dan, which afforded the highest tumor concentration, was superior to that of free MMC. Therefore, anionic mitomycin C-dextran conjugates with a high molecular weight may be useful for tumor targeting in cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2470072     DOI: 10.1023/a:1016489002393

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  22 in total

1.  Cyanogen bromide activation of polysaccharides. Effects of reaction conditions on cationic charge and ligand content.

Authors:  R L Schnaar; T F Sparks; S Roseman
Journal:  Anal Biochem       Date:  1977-05-01       Impact factor: 3.365

2.  Absorption characteristics of macromolecular prodrugs of mitomycin C following intramuscular administration.

Authors:  Y Takakura; K Mori; M Hashida; H Sezaki
Journal:  Chem Pharm Bull (Tokyo)       Date:  1986-04       Impact factor: 1.645

3.  Cellular interaction and in vitro antitumor activity of mitomycin C-dextran conjugate.

Authors:  S Matsumoto; A Yamamoto; Y Takakura; M Hashida; N Tanigawa; H Sezaki
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

4.  High molecular weight derivatives of methotrexate as chemotherapeutic agents.

Authors:  B C Chu; J M Whiteley
Journal:  Mol Pharmacol       Date:  1977-01       Impact factor: 4.436

5.  Lethal and cytokinetic effects of mitomycin C on cultured human colon cancer cells.

Authors:  B Barlogie; B Drewinko
Journal:  Cancer Res       Date:  1980-06       Impact factor: 12.701

6.  Antitumor activity of mitomycin C-dextran conjugate against various murine tumors.

Authors:  M Hashida; A Kato; T Kojima; S Muranishi; H Sezaki; N Tanigawa; K Satomura; Y Hikasa
Journal:  Gan       Date:  1981-04

7.  Disposition and pharmacokinetics of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate, in the rat.

Authors:  M Hashida; A Kato; Y Takakura; H Sezaki
Journal:  Drug Metab Dispos       Date:  1984 Jul-Aug       Impact factor: 3.922

8.  Fate of an antibody-ricin A chain conjugate administered to normal rats.

Authors:  N R Worrell; A J Cumber; G D Parnell; W C Ross; J A Forrester
Journal:  Biochem Pharmacol       Date:  1986-02-01       Impact factor: 5.858

9.  Urinary excretion characteristics of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate.

Authors:  Y Takakura; A Kato; M Hashida; K Honda; A Arimoto; K Satomura; H Sezaki
Journal:  J Pharmacobiodyn       Date:  1985-05

10.  Enhanced lymphatic delivery of mitomycin C conjugated with dextran.

Authors:  Y Takakura; S Matsumoto; M Hashida; H Sezaki
Journal:  Cancer Res       Date:  1984-06       Impact factor: 12.701

View more
  16 in total

Review 1.  Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs.

Authors:  Suphiya Parveen; Sanjeeb K Sahoo
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver.

Authors:  K Nishida; K Mihara; T Takino; S Nakane; Y Takakura; M Hashida; H Sezaki
Journal:  Pharm Res       Date:  1991-04       Impact factor: 4.200

3.  Development and pharmacokinetics of galactosylated poly-L-glutamic acid as a biodegradable carrier for liver-specific drug delivery.

Authors:  H Hirabayashi; M Nishikawa; Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

Review 4.  Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution.

Authors:  Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

5.  Evaluation of carboxymethylpullulan as a novel carrier for targeting immune tissues.

Authors:  K Masuda; M Sakagami; K Horie; H Nogusa; H Hamana; K Hirano
Journal:  Pharm Res       Date:  2001-02       Impact factor: 4.200

6.  Disposition characteristics of macromolecules in tumor-bearing mice.

Authors:  Y Takakura; T Fujita; M Hashida; H Sezaki
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

7.  Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting.

Authors:  M Nishikawa; A Kamijo; T Fujita; Y Takakura; H Sezaki; M Hashida
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

8.  Pharmacokinetics and preventive effects of targeted catalase derivatives on hydrogen peroxide-induced injury in perfused rat liver.

Authors:  Yoshiyuki Yabe; Naoki Kobayashi; Makiya Nishikawa; Kiyoshi Mihara; Fumiyoshi Yamashita; Yoshinobu Takakura; Mitsuru Hashida
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

9.  Design for cell-specific targeting of proteins utilizing sugar-recognition mechanism: effect of molecular weight of proteins on targeting efficiency.

Authors:  M Nishikawa; H Hirabayashi; Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1995-02       Impact factor: 4.200

Review 10.  Advances in lymphatic imaging and drug delivery.

Authors:  Satish K Nune; Padmaja Gunda; Bharat K Majeti; Praveen K Thallapally; M Laird Forrest
Journal:  Adv Drug Deliv Rev       Date:  2011-06-28       Impact factor: 17.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.